Mentions
Extended reach
Total likes
Video views
AI synopsis
The reviews convey excitement about the research, with phrases like 'thrilled' and 'breakthrough', while citing specific studies such as the HOPE trial and mentioning how the new antibody targets PACAP, a promising molecule. The tone and choice of words reflect strong support and anticipation for clinical advances.
Most discussions express strong support and optimism about the research, highlighting its significance for migraine treatment.
Posts show high interest, referencing studies, trial phases, and potential breakthroughs with enthusiasm.
Many participants delve into details about the trial results and the novel mechanism, indicating deep engagement.
The discussions emphasize the potential for this research to influence migraine prevention strategies, signaling high impact.
In the HOPE trial, researchers assessed the efficacy and safety of the humanized monoclonal antibody Lu AG09222, a candidate migraine-prevention drug, in participants with migraine. Full trial results and Plain Language Summary: https://t.co/3It44s8Pjm https://t.co/qkq1PI9T6h
Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Paper of the Month' in the EAN newsletter! Advancing the science of migraine treatment! @EANeurology @Rigshospitalet https://t.co/nJpT6QTTVn
Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibody Treatment for Migraine https://t.co/ggD7St8si6 #Neurology https://t.co/PwBczVfHED
October's #EANPOTM highlights a breakthrough in #migraine prevention. ➡️A phase 2 study by Ashina et al. shows Lu AG09222, a monoclonal antibody targeting PACAP, significantly reduces migraine days in patients unresponsive to previous treatments.
A study published in the New England Journal of Medicine finds a single IV infusion of a Monoclonal Antibody targeting PACAP reduced monthly migraine days better than placebo. In this Migraine Minute News Update Molly O'Brien explains. Read More: https://t.co/nMgIAkzGtA https://t.co/xuN9GGJbtP
Are you tired of preventive migraine treatments that don't work? A study in The New England Journal of Medicine introduces a monoclonal antibody targeting a protein called PACAP, showing promising results in reducing…
Tired of ineffective migraine treatments? A study in The New England Journal of Medicine reveals a promising monoclonal antibody targeting PACAP. A single dose may significantly reduce migraine days over four weeks…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
Lee más aquí: Ashina M, Phul R, Khodaie M, Löf E, Florea I. A Monoclonal Antibody to PACAP for Migraine Prevention. N Engl J Med. 2024 Sep 5;391(9):800-809. doi: 10.1056/NEJMoa2314577. PMID: 39231342. https://t.co/pDYfdfCIEY
RT @thmonk_pf: PACAPに対するモノクローナル抗体Lu AG09222のフェーズ2試験が行われ片頭痛予防効果が示された https://t.co/bORiljbSUX
PACAPに対するモノクローナル抗体Lu AG09222のフェーズ2試験が行われ片頭痛予防効果が示された https://t.co/bORiljbSUX
RT @MigraineDisordr: A study published in the New England Journal of Medicine finds a single IV infusion of a Monoclonal Antibody targeting…
A study published in the New England Journal of Medicine finds a single IV infusion of a Monoclonal Antibody targeting PACAP reduced monthly migraine days better than placebo. In this Migraine Minute News Update Molly O'Brien explains. Read More: https://t.co/nMgIAkzGtA https://t.co/xuN9GGJbtP
RT @EANeurology: October's #EANPOTM highlights a breakthrough in #migraine prevention. ➡️A phase 2 study by Ashina et al. shows Lu AG0922…
RT @EANeurology: October's #EANPOTM highlights a breakthrough in #migraine prevention. ➡️A phase 2 study by Ashina et al. shows Lu AG0922…
RT @EANeurology: October's #EANPOTM highlights a breakthrough in #migraine prevention. ➡️A phase 2 study by Ashina et al. shows Lu AG0922…
October's #EANPOTM highlights a breakthrough in #migraine prevention. ➡️A phase 2 study by Ashina et al. shows Lu AG09222, a monoclonal antibody targeting PACAP, significantly reduces migraine days in patients unresponsive to previous treatments.
RT @TheodorosMavri2: "A new HOPE"... October's paper of the month is about HOPE phase 2 study investigating the efficacy of a monoclonal a…
RT @TheodorosMavri2: "A new HOPE"... October's paper of the month is about HOPE phase 2 study investigating the efficacy of a monoclonal a…
"A new HOPE"... October's paper of the month is about HOPE phase 2 study investigating the efficacy of a monoclonal antibody (Lu AG09222) that inhibits PACAP signalling with encouraging results. Click the link below... @MessoudAshina #PACAP #migraine https://t.co/DcuVxrryaT
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
RT @MessoudAshina: Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Pape…
Thrilled to announce that our study on the efficacy of an antibody against PACAP has been featured as the 'Research Paper of the Month' in the EAN newsletter! Advancing the science of migraine treatment! @EANeurology @Rigshospitalet https://t.co/nJpT6QTTVn
Current migraine drugs targeted on CGRP don't work for ~50% of people don't see any benefit from these drugs. Another molecule, pituitary adenylate cyclase–activating polypeptide (PACAP) looks promising.
Current migraine drugs targeted on CGRP don't work for ~50% of people--they don't see any benefit from these drugs. Another molecule, pituitary adenylate cyclase–activating polypeptide (PACAP) looks promising. https://t.co/rVTn3kZ1FO?
A Monoclonal Antibody to PACAP for Migraine Prevention https://t.co/mLNvtmbpbW
Anticuerpo monoclonal de polipéptido pituitario activador de adenil-ciclasa para la prevención de la migraña https://t.co/1NcvDalybX PMID 39231342
RT @rogelio_dm: Esperanza, es el nombre del nuevo ensayo clínico que mostró que un anticuerpo contra el ligando de PACAP reduce los días de…
Some patients with migraine cannot take existing preventive medications.
RT @NEJM: Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibo…
RT @NEJM: In the HOPE trial, researchers assessed the efficacy and safety of the humanized monoclonal antibody Lu AG09222, a candidate migr…
RT @NEJM: In the HOPE trial, researchers assessed the efficacy and safety of the humanized monoclonal antibody Lu AG09222, a candidate migr…
New humanized monoclonal antibody for preventing migraines:
A Monoclonal Antibody to PACAP for Migraine Prevention | New England Journal of Medicine https://t.co/UBz85qVM2o
A Monoclonal Antibody to PACAP for Migraine Prevention | New England Journal of Medicine https://t.co/VwxyctKr77
RT @NEJM: In the HOPE trial, researchers assessed the efficacy and safety of the humanized monoclonal antibody Lu AG09222, a candidate migr…
RT @NEJM: In the HOPE trial, researchers assessed the efficacy and safety of the humanized monoclonal antibody Lu AG09222, a candidate migr…
RT @NEJM: In the HOPE trial, researchers assessed the efficacy and safety of the humanized monoclonal antibody Lu AG09222, a candidate migr…
In the HOPE trial, researchers assessed the efficacy and safety of the humanized monoclonal antibody Lu AG09222, a candidate migraine-prevention drug, in participants with migraine. Full trial results and Plain Language Summary: https://t.co/3It44s8Pjm https://t.co/qkq1PI9T6h
RT @MariosGeorgakis:
A Monoclonal Antibody to PACAP for Migraine Prevention #science #publication #research #publications https://t.co/R2EpIxEMBD
RT @NEJM: Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibo…
Exciting phase 2 trial in migraine of a new infusional monoclonal antibody against the PACAP ligand. This is a different target to prev trialed therapies. Efficacious vs placebo in treatment-experienced pts with migraine, and no major serious AEs. https://t.co/LmNcMud9M7
RT @NEJM: Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibo…
PACAPは精細胞にも分布してるので、そのあたりの影響とかも多少気になります。ちなみに日本人が発見したVIP類似のペプチドホルモンです。 https://t.co/AHhembQSEb
RT @MessoudAshina:
RT @NEJM: Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibo…
RT @NEJM: Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibo…
RT @NEJM: Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibo…
RT @NEJM: Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibo…
Original Article: A Monoclonal Antibody to PACAP for Migraine Prevention (HOPE) https://t.co/3It44s8Pjm Editorial: A New Antibody Treatment for Migraine https://t.co/ggD7St8si6 #Neurology https://t.co/PwBczVfHED